Login
ELI LILLY & Co logo

ELI LILLY & Co

lilly.com

What Do They Do?

Develops, manufactures, and sells medicines for diabetes, cancer, and other conditions to wholesalers and healthcare providers.

How Do They Make Money?

Lilly sells medicines to customers, who pay after products ship. It also receives collaboration profit shares, royalties tied to partners' product sales, upfront and milestone payments, and proceeds from selling product rights.

revenue
SegmentShareRevenue
Net product revenue
Sold outright

94%
FY2022: 89%
Collaboration and Other Revenue
Mix
6.5%
FY2022: 11%

Who Are Their Customers?

Most medicines go through wholesalers serving pharmacies, healthcare professionals, and hospitals; Lilly also works with insurers and health-plan organizations on access and rebates. In some jurisdictions, LillyDirect offers patients delivery of select medicines dispensed by third-party pharmacies.

Do Revenues Turn Into Profits?

Yes. It kept 32 cents of every revenue dollar as net income in FY2025 and turned 14 cents into free cash flow.

Operating income, FY2025
39% of revenue
▲ +103% vs FY2024 ($12.7B, 28%)
Net income, FY2025
32% of revenue
▲ +95% vs FY2024 ($10.6B, 24%)
Free cash flow, FY2025
14% of revenue
▲ +139% vs FY2024 ($3.8B, 8%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +39%
vs $17.6B in Q3 FY2025
Net income
▲ +16%
vs $5.6B in Q3 FY2025
Net product revenue share of revenue vs 92.8% in Q3 FY2025
  • Aug 5, 2026 Raised full-year guidance and completed multiple acquisitions Raised 2026 revenue and EPS guidance, completed acquisitions including Orna Therapeutics and Centessa Pharmaceuticals, then completed infectious-disease acquisitions after quarter-end and agreed to acquire AtaiBeckley.

Growing. Revenue grew 2.3x in 4 years, from $28.3B in FY2021 to $65.2B in FY2025, about 23% a year.

Obesity treatment The older report lists Mounjaro as a diabetes treatment; the latest report also lists Zepbound for obesity and overweight, adding a named use for tirzepatide.

Revenue over time
Net product revenue Collaboration and Other Revenue Collaboration and other revenue associated with prior period transfers of intellectual property
$100B$50B$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support